Trial · NCT05110001

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

NCT05110001, Phase 3, Completed, University of California, San Francisco; results first posted 2026-01-30

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction. Trials, record NCT05110001. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05110001

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
NCT number: NCT05110001
Status: Completed
Phases: Phase 3
Enrollment: 330 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Acanthamoeba Keratitis, Fungal Keratitis
Interventions: Moxifloxacin Ophthalmic, Chlorhexidine Gluconate, Natamycin, Rose Bengal, Placebo
First posted: 2021-11-05
Last updated: 2026-09-03
Results first posted: 2026-01-30

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Best Spectacle-Corrected Visual Acuity	6 Months	Best Spectacle-Corrected Visual Acuity
Secondary	Best Spectacle-Corrected Visual Acuity	3 Weeks, 3 Months, 12 Months	Best Spectacle-Corrected Visual Acuity
Secondary	Scar Size	3 Weeks, 3 Months, 6 Months 12 Months	Geometric Mean

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Best Spectacle-Corrected Visual Acuity	6 Months		logMAR	MEAN
SECONDARY	Best Spectacle-Corrected Visual Acuity	3 Weeks, 3 Months, 12 Months	Loss to follow up	logMAR	MEAN
SECONDARY	Scar Size	3 Weeks, 3 Months, 6 Months 12 Months	Loss to follow up or CP/TPK	mm	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Best Spectacle-Corrected Visual Acuity	Standard Therapy		0.614	Standard Deviation 0.658	logMAR
Best Spectacle-Corrected Visual Acuity	Cross-Linking With Rose Bengal (RB-PDT)		0.666	Standard Deviation 0.675	logMAR
Best Spectacle-Corrected Visual Acuity	Standard Therapy	3-week	0.821	Standard Deviation 0.630	logMAR
Best Spectacle-Corrected Visual Acuity	Cross-Linking With Rose Bengal (RB-PDT)	3-week	0.855	Standard Deviation 0.617	logMAR
Best Spectacle-Corrected Visual Acuity	Standard Therapy	3-month	0.700	Standard Deviation 0.661	logMAR
Best Spectacle-Corrected Visual Acuity	Cross-Linking With Rose Bengal (RB-PDT)	3-month	0.772	Standard Deviation 0.673	logMAR
Best Spectacle-Corrected Visual Acuity	Standard Therapy	12- month	0.531	Standard Deviation 0.662	logMAR
Best Spectacle-Corrected Visual Acuity	Cross-Linking With Rose Bengal (RB-PDT)	12- month	0.611	Standard Deviation 0.669	logMAR
Scar Size	Standard Therapy	3-weeks	3.84	Standard Deviation 1.64	mm
Scar Size	Cross-Linking With Rose Bengal (RB-PDT)	3-weeks	3.37	Standard Deviation 1.35	mm

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Standard Therapy	165
Overall Study	STARTED	Cross-Linking With Rose Bengal (RB-PDT)	165
Overall Study	COMPLETED	Standard Therapy	149
Overall Study	COMPLETED	Cross-Linking With Rose Bengal (RB-PDT)	148
Overall Study	NOT COMPLETED	Standard Therapy	16
Overall Study	NOT COMPLETED	Cross-Linking With Rose Bengal (RB-PDT)	17

Source ClinicalTrials.gov

Adverse events16

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Increase in hypopyon (increase >2mm)	Eye disorders	Standard Therapy	6	165
other	Increase in hypopyon (increase >2mm)	Eye disorders	Cross-Linking With Rose Bengal (RB-PDT)	7	165
other	Increase in the longest diameter of infiltrate (>50% increase from baseline and >1mm)	Eye disorders	Standard Therapy	10	165
other	Increase in the longest diameter of infiltrate (>50% increase from baseline and >1mm)	Eye disorders	Cross-Linking With Rose Bengal (RB-PDT)	14	165
other	Progressive corneal thinning, < 50% of enrollment thickness	Eye disorders	Standard Therapy	1	165
other	Progressive corneal thinning, < 50% of enrollment thickness	Eye disorders	Cross-Linking With Rose Bengal (RB-PDT)	3	165
other	Other	Eye disorders	Standard Therapy	0	165
other	Other	Eye disorders	Cross-Linking With Rose Bengal (RB-PDT)	1	165
serious	Non-elective surgery, hospitalization, or loss of function	Injury, poisoning and procedural complications	Standard Therapy	0	165
serious	Non-elective surgery, hospitalization, or loss of function	Injury, poisoning and procedural complications	Cross-Linking With Rose Bengal (RB-PDT)	1	165

1 to 10 of 16Source ClinicalTrials.gov

See all 16 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Standard Therapy	1	165
Total, all-cause mortality	Cross-Linking With Rose Bengal (RB-PDT)	0	165
Total, other adverse events	Standard Therapy	17	165
Total, other adverse events	Cross-Linking With Rose Bengal (RB-PDT)	25	165
Total, serious adverse events	Standard Therapy	31	165
Total, serious adverse events	Cross-Linking With Rose Bengal (RB-PDT)	36	165

Source ClinicalTrials.gov

Papers4

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
39011096	DERIVED	PubMed
39192339	DERIVED	PubMed
41561665	DERIVED	PubMed
42348235	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
UG1EY028518	Steroids and Cross-linking for Ulcer Treatment (SCUT II)	LIETMAN, THOMAS M; ROSE-NUSSBAUMER, JENNIFER	UNIVERSITY OF CALIFORNIA, SAN FRANCISCO	NATIONAL EYE INSTITUTE	2019 to 2023

Source NIH RePORTER

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): deaths from any cause	Trial comparisons
Standard Therapy vs Cross-Linking With Rose Bengal (RB-PDT): serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT05110001

GET https://conductscience.org/api/trials/v1/NCT05110001/registered

API reference For AI assistants